Clinical and molecular diagnosis of mosaic Neurofibromatosis type 1: next generation

Silke Hollants, Eric Legius(Center for Human Genetics), Martin U. Schuhmann(University Children's Hospital Tübingen), Ludwine Messiaen(University of Alabama at Birmingham), Maria Dêbiec‐Rychter(Center for Human Genetics), Gert Matthijs(VIB-KU Leuven Center for Cancer Biology), jarl Bastiaenen, Petra de Haas, Caroline De Groote, Carlijn Brekelmans, Kathleen Claes(KU Leuven), Isabelle Maystadt(Institute of Pathology and Genetics), Eline Beert, Charlotte Bulteel, Ophélia Maertens(American Institutes for Research), Victor Mautner(Universität Hamburg), Mariane Morren, Raoul Heller(University of Cologne), Susanne Markus
Abstract book
February 1, 2017
Cited by 0

Related Papers

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2021|558
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
|Gastroenterology|2005|494